Bispecific Or Bifunctional, Or Multispecific Or Multifunctional, Antibody Or Fragment Thereof Patents (Class 424/136.1)
  • Patent number: 11155627
    Abstract: An anti-c-Met/anti-Ang2 bispecific antibody, a composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method of preventing and/or treating a cancer in a subject including administering the anti-c-Met/anti-Ang2 bispecific antibody to the subject.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: October 26, 2021
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Hyung-Chan Kim, Kyung Eun Kim, Yoon Sook Lee, Mi Young Cho
  • Patent number: 11141471
    Abstract: Disclosed are compositions of matters, cells, and treatment protocols useful for induction of anticancer responses in a patient suffering from cancer. In one embodiment the invention provides the use of NR2F6 silencing or gene editing in cord blood cells possessing anti-tumor activity in order to induce potentiated killer cells suitable for therapeutic use. In one embodiment said allogeneic cord blood killer cells are administered to initiate a cascade of antitumor immune responses, with initially responses mediated by allogeneic killer cells, and followed by endogenous immune responses.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: October 12, 2021
    Inventors: Thomas Ichim, David Koos, Harry Lander
  • Patent number: 11130808
    Abstract: Described herein are antibodies and mixtures of antibodies optionally produced by a host cell line, nucleic acids encoding the antibodies and mixtures of antibodies, host cells containing such nucleic acids, and methods of treatment using the antibodies, mixtures of antibodies, or nucleic acids encoding the antibodies or mixtures of antibodies. Also described are methods of producing mixtures of antibodies in host cells.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: September 28, 2021
    Assignee: QILU PUGET SOUND BIOTHERAPEUTICS CORPORATION
    Inventors: Wei Yan, Zhi Liu, Martin J. Pentony
  • Patent number: 11130810
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: September 28, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri-Deak, Georg Fertig, Jens Fischer, Christian Klein, Viktor Levitski, Valeria Lifke, Mario Perro, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Pablo Umana, Ildiko Wuensche, Adrian Zwick
  • Patent number: 11066483
    Abstract: By replacing the antigen-binding domain, the present inventors discovered novel polypeptide complexes that retain BiTE's strong anti-tumor activity and excellent safety properties, as well as have long half-life in blood and can damage various different target cells.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: July 20, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Junichi Nezu, Takahiro Ishiguro, Atsushi Narita, Akihisa Sakamoto, Yumiko Kawai, Tomoyuki Igawa, Taichi Kuramochi
  • Patent number: 11053305
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: July 6, 2021
    Assignee: Q32 Bio Inc.
    Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
  • Patent number: 11053316
    Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: July 6, 2021
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Patent number: 11033590
    Abstract: The present invention provides compositions and methods for treating joint disorders that are characterized by an inflammatory component. In some aspects, the compositions and methods are to prevent the progression of osteoarthritis and other arthritides and to treat osteoarthritis and other arthritides in a mammalian joint.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: June 15, 2021
    Assignee: ORTHOBIO THERAPEUTICS, INC.
    Inventors: Peter J. Millett, Iain Alasdair Russell, Matthew J. Allen
  • Patent number: 11007250
    Abstract: The present disclosure provides methods and kits for treating pain. More particularly, the present disclosure relates to methods of using PD-L1/PD-1-associated compounds to treat pain and/or bone destruction from bone cancer, and associated kits. The present disclosure also provides methods to assess the efficacy of compounds to suppress PD-1-associated nociceptive neuron activity.
    Type: Grant
    Filed: May 12, 2018
    Date of Patent: May 18, 2021
    Assignee: Duke University
    Inventors: Ru-Rong Ji, Gang Chen, Zilong Wang, Changyu Jiang, Kaiyuan Wang
  • Patent number: 11001635
    Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulators, angiogenesis pathway regulators and/or TGF pathway regulators are disclosed. Also disclosed are methods for treating proliferative disorders, infections, and immunological disorders with the antitumor antagonists described herein.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: May 11, 2021
    Assignee: Gensun Biopharma Inc.
    Inventors: Jackie Sheng, Bo Liu, Margaret Karow
  • Patent number: 11001628
    Abstract: The present application n relates to a pharmaceutical composition comprising a PD-1 antibody and an M-CSF antibody. The combination can be administered independently or separately, in a quantity which is therapeutically effective for the treatment of cancer.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: May 11, 2021
    Assignee: NOVARTIS AG
    Inventors: Marie-Louise Fjaellskog, John Scott Cameron, Zhu Cao, Daniela Cipolletta, Kenzie MacIsaac
  • Patent number: 10973914
    Abstract: A polypeptide is disclosed that binds tumor-associated antigens (TAA) on the surface of cancer cells and a NKG2D receptor. The NKG2D receptor is expressed on the surfaces of killer cells such as natural killer cells, T cells, natural killer T cells, and gamma delta T cells. In some cases, the TAA is CS-1 or EGFRvIII. Also disclosed are polynucleotides encoding the disclosed polypeptides, vectors comprising the disclosed polynucleotides, and host cells comprising the disclosed vectors. Also disclosed are bivalent antibodies comprising the disclosed polypeptides. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies. Also disclosed are methods of treating cancer in a subject using the disclosed bi-specific antibodies.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: April 13, 2021
    Assignee: OHIO STATE INNOVATION FOUNDATION
    Inventors: Jianhua Yu, Michael Caligiuri, Wing Keung Chan
  • Patent number: 10968276
    Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: April 6, 2021
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Patent number: 10941190
    Abstract: Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes located on a single molecule or located on different molecules.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: March 9, 2021
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Whitney Shatz, Domingos Ng
  • Patent number: 10906955
    Abstract: The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors. Also provided are methods for use of these recombinant ROBO2 proteins.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: February 2, 2021
    Assignees: Pfizer Inc., Boston Medical Center Corporation
    Inventors: Stephen Berasi, Janet Elizabeth Buhlmann, Nathan Higginson-Scott, Michael Shamashkin, Matthew Russo, Stefano V. Gulla, Zong Sean Juo, Sreekumar R. Kodangattil, Weining Lu, Xueping Fan, David J. Salant
  • Patent number: 10899799
    Abstract: The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)n (I) wherein M, T, B and n ore as defined in claim 1.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: January 26, 2021
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Sylvie Bay, Claude Leclerc, Richard Lo-Man
  • Patent number: 10894830
    Abstract: The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: January 19, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Raluca Verona, Gordon Powers, Nina Chi Sabins, Nikki A DeAngelis, Sandra Santulli-Marotto, Karla R Wiehagen, Sheng-Jiun Wu, Catherine Ferrante, Enrique Zudaire Ubani
  • Patent number: 10870702
    Abstract: Provided herein is a method for determining cancer treatment using an immune modulating therapy in a subject in need thereof. The method comprises assessing whether a lymphatic system in a subject is dysregulated. When the lymphatic system is dysregulated, a treatment for the lymphatic system is determined before a therapeutic amount of an immune modulating therapy is administered to treat cancer in the subject. Alternatively, when the lymphatic system is dysregulated, an immune modulating therapy is selected to treat cancer in the subject, which immune modulating therapy is independent of immune-cell priming, antigen trafficking, antigen presentation, and any combination thereof. The subject may also be treated for cancer accordingly.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: December 22, 2020
    Assignee: ENSEMLBLE GROUP HOLDINGS
    Inventors: Michael David Kuo, Ching-Yu Huang
  • Patent number: 10870701
    Abstract: The present invention provides multispecific Fab fusion proteins (MSFP) that specifically bind to CD3 and EpCAM. The present invention further provides uses of the MSFPs for the preparation of pharmaceutical compositions, methods of treating cancer, and kits comprising the MSFPs. Also provided are anti-EpCAM antibodies or antigen-binding fragments thereof.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: December 22, 2020
    Assignee: Generon (Shanghai) Corporation Ltd.
    Inventors: Yumin Cui, Zhihua Huang, Hanyang Chen, Xinfeng Zhang, Bo Qi, Xiaoqiang Yan
  • Patent number: 10864180
    Abstract: The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: December 15, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Dimitrios Mathios, Betty Tyler, Drew Pardoll, Henry Brem, Michael Lim
  • Patent number: 10822428
    Abstract: An antibody is provided. The antibody comprises an Fc region and a Fab region, wherein the Fab region comprises a first covalent link between a first heavy chain and a first light chain of the Fab region and a second covalent link between a second heavy chain and a second light chain of said Fab region, wherein a position of the first covalent link relative to the first heavy chain is different to a position of the second covalent link relative to the second heavy chain. Methods of generating same and uses thereof are also provided.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: November 3, 2020
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Itai Benhar, Lilach Vaks
  • Patent number: 10815308
    Abstract: Bispecific antigen binding molecules (e.g., antibodies) that bind blood clotting factors, factor IXa (FIXa) and factor X (FX), and enhance the FIXa-catalysed activation of FX to FXa. Use of the bispecific antigen binding molecules to control bleeding, by replacing natural cofactor FVIIIa which is deficient in patients with haemophilia A.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: October 27, 2020
    Assignee: KYMAB LIMITED
    Inventors: Wei Wang, E-Chiang Lee, John Kenneth Blackwood, Roberto Magliozzi
  • Patent number: 10787500
    Abstract: Methods for purifying multispecific antibodies on interest (MAIs) that co-engage at least two different antigens or epitopes (also referred to targets, used interchangeably throughout), from compositions comprising the MAI and parental homodimeric antibody species are provided, as well as reagents which may be used to practice such methods.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: September 29, 2020
    Assignee: Adimab, LLC
    Inventors: Juergen Hermann Nett, K. Dane Wittrup, Maximiliano Vasquez
  • Patent number: 10766958
    Abstract: Provided herein are methods for managing, treating, or preventing vitiligo using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: September 8, 2020
    Assignee: Celgene Corporation
    Inventor: Garth E. Ringheim
  • Patent number: 10766967
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: September 8, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Tanja Fauti, Sabine Imhof-Jung, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Michael Molhoj, Christiane Neumann, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • Patent number: 10759870
    Abstract: Bispecific antibodies whose FIX activation-inhibiting activity is not elevated and whose FVIII cofactor function-substituting activity is elevated have been successfully discovered.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: September 1, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yuri Teranishi, Kazuki Kato, Hikaru Koga, Tomoyuki Igawa, Kazuki Yamaguchi, Tetsuhiro Soeda
  • Patent number: 10751414
    Abstract: Provided herein are methods for managing, treating, or preventing immune disorders, such as autoimmune diseases, using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: August 25, 2020
    Assignee: Celgene Corporation
    Inventors: Henry H. Chan, Eun Mi Hur, Roli Khattri, Monica Leung, Garth E. Ringheim, Peter H. Schafer
  • Patent number: 10738127
    Abstract: The present invention provides antibodies that target an E-cadherin linker segment, homologous to other segments adjacent to cell membrane in cancer cell shed proteins for diagnosis and therapy of cancers of epithelial origin. We design this peptide based in experimental observations that demonstrate shedding of E-cadherin and extracellular domains of other cell surface proteins during cancer progression and metastasis and based on our observation that a proline residue after transmembrane domain is present in many proteins on the cell surface that are targets for proteolytic processing. The corresponding antibodies were validated in vitro and in vivo using animal models and have showed no toxicity and significant tumor regression for gastric cancer, including potentiation of commercial drug, when utilized in combination.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: August 11, 2020
    Assignee: Veritas Biotecnologia LTDA
    Inventors: Sandra Rodrigues Pereira Faça, Vitor Marcel Faça
  • Patent number: 10688119
    Abstract: The present disclosure relates to inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: June 23, 2020
    Assignee: Aarhus Universitet
    Inventors: Camilla Gustafsen, Peder Sondergaard Madsen, Simon Glerup Pedersen
  • Patent number: 10683353
    Abstract: Disclosed herein are immunoglobulin fusion proteins comprising a first antibody region, a first therapeutic agent, and a first connecting peptide; wherein the first therapeutic agent is attached to the first antibody region by the connecting peptide; and wherein the connecting peptide does not comprise a region having beta strand secondary structure. The connecting peptide may comprise an extender peptide. The extender peptide may have an alpha helical secondary structure. The connecting peptide may comprise a linker peptide. The linker peptide may not comprise any secondary structure. Also disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: June 16, 2020
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Feng Wang, Yong Zhang, Yan Liu, Peter G. Schultz
  • Patent number: 10683351
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide and a host cell transformed or transfected with the polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of the antibody construct and a kit comprising the antibody construct.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: June 16, 2020
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
  • Patent number: 10669350
    Abstract: The invention relates to single domain VHH fragments which specifically bind to and inhibit superoxide dismutase and/or bind to and inhibit catalase and/or bind to and inhibit superoxide dismutase and catalase, in particular for the use in the therapy of tumor diseases.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: June 2, 2020
    Inventors: Georg Bauer, Manfred Motz
  • Patent number: 10640572
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: May 5, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Teemu T. Junttila, Robert F. Kelley, Mary A. Mathieu
  • Patent number: 10633451
    Abstract: The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: April 28, 2020
    Assignees: Hoffmann-La Roche Inc., Ludwig-Maximillians-Universität München
    Inventors: Carole Bourquin, Raffaella Castoldi, Stefan Endres, Christian Klein, Sebastian Kobold, Gerhard Niederfellner, Claudio Sustmann
  • Patent number: 10633457
    Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: April 28, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Wolfgang Schaefer, Klaus Mayer
  • Patent number: 10626190
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 21, 2020
    Assignee: Amphivena Therapeutics, Inc.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • Patent number: 10611832
    Abstract: Disclosed are methods for the reduction, prevention or treatment of cardiovascular events and/or cardiovascular diseases, including acute cardiovascular disease or chronic cardiovascular disease using anti-IL-1? binding molecules (e.g., IL-1? binding antibodies and fragments thereof). The present disclosure also relates to methods for prevention or treatment of cardiovascular events and/or cardiovascular diseases, including by reducing a cardiovascular event or disease.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: April 7, 2020
    Assignee: XOMA (US) LLC
    Inventors: Patrick J. Scannon, Alan M. Solinger, Jeffrey D. Feldstein
  • Patent number: 10556964
    Abstract: Provided are compositions comprising a MSBODY and a cytotoxic immune cell (e.g., Cytokine-induced killer cell) to form Armed Activated CIK cells (ACCs), wherein the MSBODY comprising a first antigen binding moiety that has specificity for a tumor antigen, and a second antigen binding moiety that binds to the cell. Provided are also methods preparing a composition comprising a MSBODY and a cytotoxic immune cell, and methods for treating patients with CIK cells armed with bispecific antibodies.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: February 11, 2020
    Assignee: Wuhan YZY Biopharma Co., Ltd.
    Inventors: Pengfei Zhou, Tao Wang, Liu Hu, Mi Huang, Lijuan Fang, Yang Liu
  • Patent number: 10543261
    Abstract: The present invention provides a therapeutic or prophylactic agent for cancer, containing an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of VEGF and/or a specific epitope of angiopoietin-2, wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: January 28, 2020
    Assignees: Osaka University, AnGes, Inc.
    Inventors: Hironori Nakagami, Mariko Kyutoku, Ryuichi Morishita, Hideki Tomioka
  • Patent number: 10538585
    Abstract: Herein are reported anti-ANG2 antibodies. A specific anti-ANG2 antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: January 21, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Joerg Thomas Regula
  • Patent number: 10487150
    Abstract: SIRPabodies comprise an immunoglobulin variable region, which may specifically bind a tumor antigen, viral antigen, etc., fused to a sequence comprising a binding domain of SIRP?. The binding domain of SIRP? comprises at least the N-terminal Ig-like domain of SIRP?, and may further comprise additional SIRP? sequences. The SIRPabodies find use in therapeutic methods that benefit from the combined activity of blocking CD47 activity, and antibody targeting, e.g. in the treatment of cancer, etc. In some specific embodiments, the SIRPabody comprises anti-CD20 activity and a SIRP? binding domain; anti-CD99 and a SIRP? binding domain; or anti-TIM3 activity and a SIRP? binding domain.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: November 26, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ravindra Majeti, Emily Piccione Griffin
  • Patent number: 10479831
    Abstract: This invention relates to chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: November 19, 2019
    Assignee: MacroGenics, Inc
    Inventors: Leslie S. Johnson, Ling Huang
  • Patent number: 10472419
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: November 12, 2019
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., Children's Medical Center Corporation
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Patent number: 10472427
    Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: November 12, 2019
    Assignee: Xencor, Inc.
    Inventors: John Desjarlais, Gregory Moore, Rumana Rashid, Matthew Bernett
  • Patent number: 10465006
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: November 5, 2019
    Assignee: GENMAB A/S
    Inventors: Edward Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Paul Parren
  • Patent number: 10457732
    Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: October 29, 2019
    Assignee: MEDIMMUNE, LLC
    Inventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst
  • Patent number: 10457745
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: October 29, 2019
    Assignee: Bioverativ USA Inc.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • Patent number: 10450382
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: October 22, 2019
    Assignee: Bioverativ USA Inc.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • Patent number: 10421816
    Abstract: The present invention provides a multivalent antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a constant region fragment, said constant region fragment located between two variable domains which are not a cognate pair, the heavy chain further comprising an Fc region with at least one domain selected from CH2, CH3 and combinations thereof, with the proviso that the heavy chain contains no more than one CH1 domain and only contains two variable domains, and a light chain comprising a constant region fragment located between two variable domains which are not a cognate pair, wherein said heavy and light chains are aligned to provide a first binding site formed by a first cognate pair of variable domains and a second binding site formed by a second cognate pair of variable domains.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: September 24, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Ralph Adams, Emma Dave, David Paul Humphreys
  • Patent number: 10407501
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: September 10, 2019
    Assignee: GENMAB A/S
    Inventors: Edward Norbert Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker